P-1346. Comparative Effectiveness of Parenteral Daptomycin Versus Vancomycin Among Patients with Methicillin-resistant Staphylococcus aureus (MRSA) Endogenous endophthalmitis: A Retrospective Analysis

TL;DR

This study compares daptomycin and vancomycin for treating MRSA endophthalmitis, finding similar effectiveness but notable differences in side effects.

Contribution

The study provides a comparative analysis of daptomycin and vancomycin in MRSA endophthalmitis, highlighting their safety profiles.

Findings

Daptomycin and vancomycin showed similar mortality rates in MRSA endophthalmitis patients.

Daptomycin was associated with significantly higher rates of CPK elevation and CKD stage 4/5.

Vancomycin was linked to a higher risk of embolic stroke compared to daptomycin.

Abstract

Endogenous endophthalmitis is a rare complication of Staphylococcus aureus, including its methicillin-resistant (MRSA), presents a significant clinical challenge due to its potential for irreversible vision. Vancomycin and daptomycin are commonly used systemic and intravitreal antibiotics; however, their comparative effectiveness in treating MRSA endogenous endophthalmitis remains unclear. This study aims to compare the efficacy and safety of daptomycin versus vancomycin in MRSA bacteremia with endophthalmitis.Figure 1:MortalityIn this matched cohort analysis of 200 patients with MRSA endophthalmitis (100 treated with daptomycin, 100 with vancomycin), mortality rates were similar—10% for daptomycin vs. 12% for vancomycin (risk difference -0.020; 95% CI: -0.107, 0.067; p = 0.651).Figure 2:CPK levelsCPK elevation, indicating muscle toxicity, was much higher with daptomycin (52.9% vs. 13.0%; risk difference 0.400; 95% CI: 0.243, 0.556; p < 0.0001)

Mortality

In this matched cohort analysis of 200 patients with MRSA endophthalmitis (100 treated with daptomycin, 100 with vancomycin), mortality rates were similar—10% for daptomycin vs. 12% for vancomycin (risk difference -0.020; 95% CI: -0.107, 0.067; p = 0.651).

CPK levels

CPK elevation, indicating muscle toxicity, was much higher with daptomycin (52.9% vs. 13.0%; risk difference 0.400; 95% CI: 0.243, 0.556; p < 0.0001)

A retrospective observational cohort study was conducted using the TriNetX Research Collaborative Network. Adults diagnosed with MRSA endophthalmitis were included into daptomycin and vancomycin treatment groups. Propensity score matching was performed to balance covariates between groups. Statistical analyses included Kaplan-Meier survival curves, Cox proportional hazard regression, and log-rank tests.

In this matched cohort analysis of 200 patients with MRSA endophthalmitis (100 treated with daptomycin, 100 with vancomycin), mortality rates were similar—10% for daptomycin vs. 12% for vancomycin (risk difference -0.020; 95% CI: -0.107, 0.067; p = 0.651), as were rates of blindness (13.9% vs. 13.5%; risk difference 0.004; 95% CI: -0.108, 0.115; p = 0.947), endocarditis (11.6% vs. 11.4%; risk difference 0.003; 95% CI: -0.092, 0.097; p = 0.956). Septic shock (27.0% vs. 18.5%) and bacteremia were more frequent with daptomycin, but not significantly. CPK elevation was higher in daptomycin (52.9% vs. 13.0%; risk difference 0.400; 95% CI: 0.243, 0.556; p < 0.0001), and CKD stage 4/5 occurred in 12.2% of daptomycin patients versus 0% for vancomycin (risk difference 0.122; 95% CI: 0.051, 0.193; p = 0.001). Notably, embolic stroke occurred in 0% of daptomycin patients compared to 10.4% vancomycin (risk difference -0.104; 95% CI: -0.165, -0.043; p = 0.001). Baseline characteristics were well-matched, including mean age (53.5 vs. 54 years), diabetes (55% vs. 45%), and mean BMI (29.2 vs. 28.3).

Daptomycin and vancomycin provide comparable effectiveness for major clinical outcomes in MRSA endophthalmitis, but their safety profiles differ.

All Authors: No reported disclosures

Figures